Aerie pharmaceuticals to announce fourth quarter and year end 2016 financial results and host conference call on tuesday, march 7, 2017

Irvine, calif.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), (the “company”), announced today that its fourth quarter and year end 2016 financial results will be released after the market closes on tuesday, march 7, 2017. following the release, the company will host a live conference call and webcast at 5:00 p.m. eastern time to discuss the company's financial results and provide a general business update. the live webcast and a replay may be accessed by visiting the company's website at http://investors.aeriepharma.com. please connect to the company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. alternatively, please call (888) 734-0328 (u.s.) or (678) 894-3054 (international) to listen to the live conference call. the conference id number for the live call is 61259874. please dial in approximately 10 minutes prior to the call. telephone replay will be available approximately two hours after the call. to access the replay, please call (855) 859-2056 (u.s.) or (404) 537-3406 (international). the conference id number for the replay is 61259874. the telephone replay will be available until march 14, 2017. about aerie pharmaceuticals, inc. aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. aerie's two lead product candidates are once-daiiy iop-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. the nda filing for rhopressatm (netarsudil ophthalmic solution) 0.02% was originally submitted in the third quarter of 2016 and is expected to be resubmitted near the end of the first quarter of 2017. the second product candidate, roclatantm (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of rhopressatm and widely prescribed pga latanoprost, currently has two phase 3 registration trials underway, named mercury 1 and mercury 2. if these trials are successful, a roclatantm nda filing is expected to take place near year-end 2017. aerie is also focused on the development of additional product candidates and technologies in ophthalmology.
AERI Ratings Summary
AERI Quant Ranking